{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:22:35Z","timestamp":1790032955951,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","liver.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.cld.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T10:31:07Z","timestamp":1476268267000},"page":"667-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Liver Fibrosis Reversion After Suppression of Hepatitis B Virus"],"prefix":"10.1016","volume":"20","author":[{"given":"Don C.","family":"Rockey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cld.2016.06.003_bib1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis\u2013a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9859","key":"10.1016\/j.cld.2016.06.003_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors","volume":"102","author":"Iredale","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cgh.2013.01.005","article-title":"Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies","volume":"11","author":"Rockey","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2016.06.003_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1542-3565(04)00445-8","article-title":"Antifibrotic therapy in chronic liver disease","volume":"3","author":"Rockey","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI118925","article-title":"Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing","volume":"98","author":"Rockey","year":"1996","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.cld.2016.06.003_bib7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","article-title":"Clinical evidence for the regression of liver fibrosis","volume":"56","author":"Ellis","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib8","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1600-6143.2008.02227.x","article-title":"Reversal of cardiac cirrhosis following orthotopic heart transplantation","volume":"8","author":"Crespo-Leiro","year":"2008","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.cld.2016.06.003_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"40","author":"Czaja","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"15","key":"10.1016\/j.cld.2016.06.003_bib10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.cld.2016.06.003_bib11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1572-0241.2004.30408.x","article-title":"Reversal of portal hypertension in a patient with primary biliary cirrhosis: disappearance of esophageal varices and thrombocytopenia","volume":"99","author":"El-Husseini","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM200102083440604","article-title":"Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct","volume":"344","author":"Hammel","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cld.2016.06.003_bib13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.5858\/2000-124-1599-ROHC","article-title":"Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis","volume":"124","author":"Wanless","year":"2000","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/j.cld.2016.06.003_bib14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7326\/0003-4819-127-11-199712010-00006","article-title":"Reversibility of hepatic fibrosis in autoimmune hepatitis","volume":"127","author":"Dufour","year":"1997","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0168-8278(01)00218-5","article-title":"Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B","volume":"35","author":"Kweon","year":"2001","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"9865","key":"10.1016\/j.cld.2016.06.003_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2016.06.003_bib18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jhep.2013.05.007","article-title":"Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy","volume":"59","author":"Liaw","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2016.06.003_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Shiratori","year":"2000","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2016.06.003_bib20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.cld.2016.06.003_bib22","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2016.06.003_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imj.1970.19.1.54","article-title":"Reversal of \u201ccirrhosis\u201d in idiopathic haemochromatosis following long-term intensive venesection therapy","volume":"19","author":"Powell","year":"1970","journal-title":"Australas Ann Med"},{"issue":"5","key":"10.1016\/j.cld.2016.06.003_bib24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/0016-5085(88)90379-4","article-title":"Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis","volume":"95","author":"Blumberg","year":"1988","journal-title":"Gastroenterology"},{"issue":"8397","key":"10.1016\/j.cld.2016.06.003_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(84)90295-2","article-title":"Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis","volume":"2","author":"Sorensen","year":"1984","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2016.06.003_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4269\/ajtmh.2008.78.228","article-title":"Reversibility of schistosomal periportal thickening\/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia","volume":"78","author":"Berhe","year":"2008","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.cld.2016.06.003_bib27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0168-8278(02)00103-4","article-title":"Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate","volume":"37","author":"Sohara","year":"2002","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.22351","article-title":"Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence","volume":"48","author":"Deleve","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2016.06.003_bib29","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2012.06.036","article-title":"Deactivation of hepatic stellate cells during liver fibrosis resolution in mice","volume":"143","author":"Troeger","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-2001-17557","article-title":"Stellate cell behavior during resolution of liver injury","volume":"21","author":"Iredale","year":"2001","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/jhep.2002.35279","article-title":"Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2","volume":"36","author":"Preaux","year":"2002","journal-title":"Hepatology"},{"issue":"41","key":"10.1016\/j.cld.2016.06.003_bib32","doi-asserted-by":"crossref","first-page":"38152","DOI":"10.1074\/jbc.M101980200","article-title":"15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors","volume":"276","author":"Li","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.cld.2016.06.003_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4161\/auto.8.1.18105","article-title":"Autophagy: a new player in hepatic stellate cell activation","volume":"8","author":"Thoen","year":"2012","journal-title":"Autophagy"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jhep.2011.07.010","article-title":"A\u00a0role for autophagy during hepatic stellate cell activation","volume":"55","author":"Thoen","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2016.06.003_bib35","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4161\/auto.19947","article-title":"Autophagy fuels tissue fibrogenesis","volume":"8","author":"Hernndez-Gea","year":"2012","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.cld.2016.06.003_bib36","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2011.12.044","article-title":"Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues","volume":"142","author":"Hernandez-Gea","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/jhep.2003.50097","article-title":"Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype","volume":"37","author":"Schnabl","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2016.06.003_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis","volume":"134","author":"Krizhanovsky","year":"2008","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib39","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.25744","article-title":"Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jgh.12213","article-title":"Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal","volume":"28","author":"Marcellin","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2016.06.003_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during long-term lamivudine therapy","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2016.06.003_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jhep.2004.10.006","article-title":"Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B","volume":"42","author":"Rizzetto","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib43","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2016.06.003_bib45","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1111\/j.1572-0241.2008.02086.x","article-title":"Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis","volume":"103","author":"Schiff","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2009.12.036","article-title":"Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection","volume":"52","author":"Yokosuka","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib47","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"issue":"2 Suppl 1","key":"10.1016\/j.cld.2016.06.003_bib48","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1002\/hep.21046","article-title":"Noninvasive measures of liver fibrosis","volume":"43","author":"Rockey","year":"2006","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2016.06.003_bib49","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib50","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","article-title":"Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy","volume":"123","author":"Fontana","year":"2002","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2016.06.003_bib51","first-page":"1419","article-title":"Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients","volume":"38","author":"Schiff","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2016.06.003_bib52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis","volume":"52","author":"Shim","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2016.06.003_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2016.06.003_bib54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2016.06.003_bib55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis","volume":"19","author":"Chan","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"issue":"5","key":"10.1016\/j.cld.2016.06.003_bib56","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gutjnl-2012-302024","article-title":"Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis","volume":"62","author":"Zoutendijk","year":"2013","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2016.06.003_bib57","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2009.07.047","article-title":"Trends in waiting list registration for liver transplantation for viral hepatitis in the United States","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2016.06.003_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hepres.2005.02.006","article-title":"Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients","volume":"32","author":"Matsumoto","year":"2005","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.cld.2016.06.003_bib59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00535-009-0024-z","article-title":"Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"44","author":"Miyake","year":"2009","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2016.06.003_bib60","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2016.06.003_bib61","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/gut.2010.221846","volume":"60","author":"Papatheodoridis","year":"2011","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.cld.2016.06.003_bib62","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326116300484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326116300484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T05:09:22Z","timestamp":1657429762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326116300484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1089326116300484"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2016.06.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver Fibrosis Reversion After Suppression of Hepatitis B Virus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}